The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 869 Weight Management articles
A groundbreaking study reveals that switching to an oral GLP-1 medication like orforglipron can help individuals maintain a significant portion of their weight loss achieved with injectable therapies, offering a new avenue for long-term obesity management.
A comprehensive analysis of the STEP trials reveals that once-weekly semaglutide significantly benefits older adults with obesity, leading to substantial weight loss and improvements in key cardiometabolic markers. This article delves into the findings, implications, and considerations for this important demographic.
The global GLP-1 meal replacement market is experiencing explosive growth, projected to reach USD 10.9 billion by 2036. This surge is directly linked to the increasing adoption of GLP-1 medications like semaglutide and tirzepatide, alongside a growing consumer preference for convenient, nutrient-dense, and high-protein nutrition solutions designed to support weight management and reduced-appetite lifestyles.
Polycystic Ovary Syndrome (PCOS), a condition affecting millions of women, is undergoing a significant renaming to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change aims to better reflect the condition's complex interplay with endocrine and metabolic systems, potentially improving diagnosis and treatment.
Hims & Hers reports Q1 results. See how financial growth and regulatory shifts affect patient access to semaglutide, tirzepatide, and peptide therapy.
The quest for physical perfection is driving a new trend among teen boys and young men: the use of unapproved peptides. This article delves into the motivations, the substances involved, and the significant health concerns surrounding this practice.
Comedian Greg Davies reveals the physical and psychological effects of stopping Ozempic after significant weight loss, offering insights for patients on peptide therapy.
With healthcare costs projected to jump another 9% next year, driven significantly by GLP-1 medications like semaglutide and tirzepatide, employers face unprecedented budget pressure. This article explores why reactive cost-cutting fails and how investing upstream in robust primary care coordination is the key to sustainable financial health and better patient outcomes.
Navigating weight loss with GLP-1 medications such as semaglutide and tirzepatide requires careful attention to lifestyle choices. This guide details 8 crucial things to avoid to ensure you experience the full benefits and fewer side effects.
